Literature DB >> 8422302

Phase II trial with ifosfamide in pancreatic cancer.

J A Wils, T Kok, D J Wagener, E Francois, J Selleslags, N Duez.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8422302     DOI： 10.1016/0959-8049(93)90201-p

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  3 in total

Review 1.  Multimodal therapies in ductal pancreatic cancer. The future.

Authors:  K H Link; F Gansauge; J Pillasch; H G Beger
Journal:  Int J Pancreatol       Date:  1997-02

2.  Ifosfamide treatment as a 10-day continuous intravenous infusion.

Authors:  H J Keizer; J Ouwerkerk; K Welvaart; C J van der Velde; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

Review 3.  Encapsulated cells expressing a chemotherapeutic activating enzyme allow the targeting of subtoxic chemotherapy and are safe and efficacious: data from two clinical trials in pancreatic cancer.

Authors:  J Matthias Löhr; Stephan L Haas; Jens C Kröger; Helmut M Friess; Raimund Höft; Peter E Goretzki; Christian Peschel; Markus Schweigert; Brian Salmons; Walter H Gunzburg
Journal:  Pharmaceutics       Date:  2014-08-11       Impact factor: 6.321
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.